Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients ≥ Age 60 With Advanced Stage Diffuse Large B-Cell NHL: A Phase II Study

NCT00107380 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT00107380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00107380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients ≥ Age 60 With Advanced Stage Diffuse Large B-Cell NHL: A Phase II Study
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
December 31, 2015
Enrollment
86 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma